Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments
(1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC).
Financial Results:
- Piramal Pharma Ltd. reported Total Income for Q4FY23 of ₹ 2,188 Crores up from ₹ 2209 Crore year on year, a fall of 1%.
- Total Expenses for Q4FY23 of ₹ 2,101 Crores up from ₹ 1,956 Crores year on year, rise of 7%.
- Consolidated Net Profit of ₹ 50 Crores, down 75% from ₹ 204 Crores in the same quarter of the previous year.
- The Earnings per Share is ₹ 0.42, up 76% from ₹ 1.72 in the same quarter of the previous year.